Financial Performance - The company's operating revenue for 2024 reached ¥3,500,831,286.92, representing a year-on-year increase of 5.72% compared to ¥3,311,472,606.54 in 2023[24] - The net profit attributable to shareholders for 2024 was ¥722,550,720.15, a significant increase of 27.19% from ¥568,109,302.85 in the previous year[24] - The basic earnings per share for 2024 was ¥1.287, up 27.17% from ¥1.012 in 2023[26] - The company's total assets as of the end of 2024 amounted to ¥5,016,843,207.73, reflecting a 5.13% increase from ¥4,771,917,373.39 at the end of 2023[25] - The net assets attributable to shareholders increased by 10.09% to ¥3,072,526,287.29 at the end of 2024, compared to ¥2,791,040,844.65 at the end of 2023[25] - The company reported a net cash flow from operating activities of ¥875,864,233.13 for 2024, an increase of 7.68% from ¥813,428,748.87 in 2023[24] - The weighted average return on equity for 2024 was 24.80%, an increase of 3.52 percentage points from 21.28% in 2023[26] Dividend Policy - The company plans to distribute a cash dividend of ¥0.90 per share, totaling approximately ¥510,403,937.40, which accounts for 70.64% of the annual net profit attributable to shareholders[6] - The total number of shares for the cash dividend distribution is 567,115,486, with a cash dividend payout of ¥451,147,133.60 for the fiscal year 2023, based on a total share capital of 567,140,242 shares[159] - Over the last three accounting years, the cumulative cash dividend amount (including tax) reached ¥1,300,007,084.00, with an average annual net profit of ¥585,321,539.03, resulting in a cash dividend ratio of 222.10%[167] - The company has established a three-year shareholder dividend return plan for 2024-2026 to ensure a stable and predictable return mechanism for investors[158] - The company has not proposed a stock dividend or capital reserve transfer to increase share capital for the fiscal year 2024, opting to carry forward the remaining distributable profits to the next year[160] Research and Development - The company has accelerated its digital and intelligent upgrades, enhancing management efficiency through automation technologies[35] - The company is focusing on research and development in major disease areas, including orthopedics and respiratory systems, to strengthen its product line[36] - Research and development expenses increased by 19.95% to 131.53 million RMB, indicating a focus on innovation[68] - The company reported a significant increase in R&D expenditures for projects LR003, LR015, LR002, and LR020, with year-on-year increases of 41.99%, 126.73%, 366.43%, and 362.85% respectively[109] - The company plans to prioritize R&D innovation in traditional Chinese medicine and high-end formulations, particularly in orthopedics and chronic disease management[120] Product Development and Market Strategy - The company completed the construction of production lines for tablets and oral liquid formulations at its Xinyang branch, laying the foundation for future product expansion[35] - The company obtained drug registration certificates for new products, including Montelukast Sodium Chewable Tablets and Metformin Hydrochloride Sustained-Release Tablets[36] - The company signed a letter of intent to acquire controlling interest in Yingu Pharmaceutical Co., Ltd., enhancing its product matrix with high-tech external preparations[37] - The company launched new products such as Tadalafil tablets and Montmorillonite powder, contributing to its growth momentum during the reporting period[39] - The company is focusing on expanding its product lineup in major therapeutic areas such as orthopedics, respiratory, dermatology, and digestive systems[98] Market Presence and Brand Recognition - The company’s pediatric brand "Little Antelope" is being promoted through major media channels, including CCTV and social media, to deepen brand awareness[38] - The company’s "Two Tigers" brand won the Best-Selling Brand Award in the Chinese drug retail market for 2024, indicating strong brand recognition[38] - The company has developed nearly 5,000 hospitals and grassroots medical institutions for its prescription drug business, enhancing its market presence[39] - The company’s unique product, Tongluo Qutong Ointment, is included in the National Essential Drug List and National Medical Insurance Directory, highlighting its market position in orthopedics[61] Operational Efficiency and Management - The company emphasizes a strict supplier management system to ensure the quality and stability of raw material supplies, which is crucial for production[58] - The company follows a "sales-driven production" model, aligning production tasks with market demand and inventory levels to optimize efficiency[59] - The company has a diverse sales model that includes distribution and direct sales, leveraging e-commerce platforms for product promotion[59] - The company is advancing its smart manufacturing capabilities, integrating modern information management systems to enhance production efficiency[65] Risk Management and Compliance - The company does not foresee any significant risks that could materially impact its operations during the reporting period[9] - The company will strengthen its internal control systems to mitigate risks and enhance overall risk management capabilities[119] - The company anticipates potential risks from policy changes in the pharmaceutical industry, emphasizing the need for enhanced management and compliance[126] - The company will implement strict quality management systems to mitigate risks associated with product quality and ensure compliance with national regulations[127] Corporate Governance - The company maintains a robust corporate governance structure, ensuring compliance with relevant laws and regulations while enhancing operational quality[130] - The company’s board of directors operates effectively, with clear responsibilities and adherence to legal requirements, ensuring independent oversight of management activities[132] - The company has established a comprehensive internal control system covering governance, management, finance, human resources, and auditing[133] - The company’s annual financial report received an unqualified opinion, indicating transparency and adherence to disclosure requirements[133] Social Responsibility and Environmental Impact - The company invested 1.1414 million yuan in environmental protection during the reporting period[177] - The company has reported a total donation of 2.1541 million yuan for public welfare projects, including 0.9030 million yuan in cash and 1.2511 million yuan in material donations[185] - The company has implemented measures to reduce carbon emissions, including regular analysis of energy consumption and promoting water conservation[184] - The company has completed the installation and acceptance of video monitoring and online monitoring equipment for wastewater discharge[179]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,020,755,870.55, representing a 12.29% increase compared to CNY 909,046,867.70 in the same period last year[3]. - The net profit attributable to shareholders was CNY 216,817,540.12, up 13.89% from CNY 190,378,639.92 year-on-year[3]. - Basic earnings per share rose to CNY 0.383, a 12.65% increase from CNY 0.340 in the same period last year[3]. - Total operating revenue for Q1 2025 reached ¥1,020,755,870.55, an increase of 12.3% compared to ¥909,046,867.70 in Q1 2024[18]. - Net profit for Q1 2025 was ¥216,733,789.10, representing a 13.9% increase from ¥190,328,634.98 in Q1 2024[19]. - Basic earnings per share for Q1 2025 were ¥0.383, compared to ¥0.340 in Q1 2024, indicating a growth of 12.6%[20]. - The company reported a comprehensive income total of ¥223,044,911.33 for Q1 2025, compared to ¥140,894,063.49 in Q1 2024, reflecting a significant increase of 58.3%[20]. Cash Flow - The net cash flow from operating activities increased significantly by 161.91%, reaching CNY 117,615,900.12, compared to CNY 44,906,293.79 in the previous year[3]. - Cash received from sales of goods and services in Q1 2025 was ¥895,511,232.10, an increase from ¥761,878,217.97 in Q1 2024, marking a growth of 17.5%[22]. - Operating cash inflow totaled $903,232,099.55, an increase from $809,623,301.08 in the previous period[23]. - Net cash flow from operating activities reached $117,615,900.12, significantly up from $44,906,293.79[23]. - The ending cash and cash equivalents balance was $570,929,618.67, down from $1,466,278,009.71[24]. - The company experienced a net decrease in cash and cash equivalents of $657,448,187.33 during the period[24]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,410,895,780.92, reflecting a 7.85% increase from CNY 5,016,843,207.73 at the end of the previous year[4]. - Total liabilities rose to ¥2,067,027,296.35, compared to ¥1,936,551,143.73 in the previous period, reflecting an increase of 6.8%[14]. - The total equity attributable to shareholders was CNY 3,311,522,505.91, which is a 7.78% increase from CNY 3,072,526,287.29[4]. - Shareholders' equity increased to ¥3,343,868,484.57, up from ¥3,080,292,064.00, indicating a growth of 8.6%[15]. Investments and Acquisitions - The company approved the acquisition of 90% equity in Yingu Pharmaceutical Co., Ltd. for RMB 703,908,000, which was completed in March 2025[10]. - The company's intangible assets increased significantly from RMB 203,746,216.32 to RMB 317,123,551.29, marking an increase of approximately 55.5%[13]. - The goodwill recorded as of March 31, 2025, was RMB 482,016,236.04, indicating the company's strategic investments in acquisitions[13]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 36,288[8]. - The largest shareholder, Henan Lingrui Group Co., Ltd., holds 121,817,898 shares, accounting for 21.48% of the total shares, with 26,930,000 shares pledged[8]. - The company has not reported any changes in the top 10 shareholders or their participation in margin financing and securities lending activities[10]. Operating Costs and Expenses - Total operating costs for Q1 2025 were ¥780,335,122.23, up from ¥696,497,752.04 in Q1 2024, reflecting a growth of 12.0%[18]. - Research and development expenses for Q1 2025 were ¥22,799,572.17, compared to ¥20,393,113.38 in Q1 2024, showing an increase of 11.8%[19].

2024 年度独立董事述职报告 (李慧) 作为河南羚锐制药股份有限公司(以下简称"公司")的独立董事,2024_年, 本人按照《公司法》《上市公司独立董事管理办法》《上海证券交易所上市公司自 律监管指引第 1 号 -- 规范运作》等法律法规、规范性文件以及《公司章程》、 《独立董事工作制度》等规定,勤勉尽责地履行独立董事职责,审慎行使公司和 股东所赋予的权利,出席了公司相关会议,认真审议董事会各项议案,充分发挥 独立董事作用,对董事会的科学决策、规范运作起到了积极作用,切实维护全体 股东尤其是中小股东的合法权益。现将本人 2024年度履职情况报告如下: 一、独立董事的基本情况 (一)个人履历 李慧,女,汉族,1967年7月生,博士。现任中国中医科学院首席研究员、 河南羚锐制药股份有限公司独立董事。 (二)是否存在影响独立性的情况说明 河南羚锐制药股份有限公司 作为公司的独立董事,本人具有履行独立董事职责所必需的专业能力和工作 经验,具备《上市公司独立董事管理办法》等法律法规所要求的独立性,并在履 职中保持客观、独立的专业判断,不存在影响独立性的情况。 二、独立董事年度履职概况 (一) 2024年度出席会议情况 ...

2024年 (杨 ) (以 " ")的 ,2024年 , 1号—— ,勤 ,审 ,出 ,认 ,充 ,对 ,切 2024年 : (一 )独 ,男 ,汉 ,1969年 12月 ,工 ,中 ,2023年 5月 (二 )是 ,本 ,具 ,并 ,不 (一 )2024年 1、 2024年 ,公 8次 2次 ,本 ,亲 ,积 ,本 ,充 ,会 ,与 ,积 ,利 ,对 ,没 ,2024年 ,重 2、 2024年 ,公 1次 1次 5次 5次 ,本 ,积 ,并 ,就 ,以 ,为 3、 2024年 ,公 1次 ,本 ,就 2024 2025年 ,本 ,切 (二 )现 2024年 ,本 ,充 ,并 ,与 ,及 ,积 , ,为 ,主 :在 ,相 ,充 ,为 (三)与 ,本 ,督 ;与 ,充 ,履 , ,切 (一 )关 2024年 11月 29日 ,公 2024 2025年 ,本 ,经 ,本 ,关 ,定 ,不 ,也 ;在 ,关 ,符 (二 )披 ,本 , ,符 ;公 ,内 ,符 (三 )聘 (四 )与 ,本 ,与 ,密 ,督 , ,提 ,不 ,切 ,经 ,董 ,公 (特 )为 2024年 , ,公 (四 )会 , ,能 ,不 ,不 ( ...

根据《上市公司独立董事管理办法》《上海证券交易所股票上市规则》《上海 证券交易所上市公司自律监管指引第 1 号——规范运作》等要求，公司董事会就 公司独立董事李慧、杨钧、张钦昱 2024 年度独立性情况进行评估并出具如下专 项意见: 经核查公司独立董事李慧、杨钧、张钦昱的任职经历以及签署的相关自查文 件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公 司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进 行独立客观判断的关系，因此，公司独立董事符合《上市公司独立董事管理办法》 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》中对独立董事 独立性的相关要求。 河南羚锐制药股份有限公司董事会 河南羚锐制药股份有限公司 二○二五年四月二十四日 董事会对独立董事 2024 年度独立性情况评估的专项意见 ...

河南羚锐制药股份有限公司 2024 年度独立董事述职报告 (张敏昱) 作为河南羚锐制药股份有限公司(以下简称"公司")的独立董事,2024年, 本人按照《公司法》《上市公司独立董事管理办法》《上海证券交易所上市公司自 律监管指引第 1 号 -- 规范运作》等法律法规、规范性文件以及《公司章程》、 《独立董事工作制度》等规定,勤勉尽责地履行独立董事职责,审慎行使公司和 股东所赋予的权利,出席了公司相关会议,认真审议董事会各项议案,充分发挥 独立董事作用,对董事会的科学决策、规范运作起到了积极作用,切实维护全体 股东尤其是中小股东的合法权益。现将本人 2024年度履职情况报告如下: 一、 独立董事基本情况 报告期内,因独立董事梅夏英先生申请辞去独立董事职务,经公司第九届董 事会第七次会议及 2023年年度股东大会审议通过,补选本人为公司独立董事。 张钦昱,男,汉族,1985年5月生,法学博士。现任中国政法大学经济法 研究所所长,河南羚锐制药股份有限公司独立董事。 (二)是否存在影响独立性的情况说明 作为公司的独立董事,本人具有履行独立董事职责所必需的专业能力和工作 经验,具备《上市公司独立董事管理办法》等法律法规 ...

羚锐制药（600285）公告，2024年营业收入35.01亿元，同比增长5.72%。归属于上市公司股东的净利润 7.23亿元，同比增长27.19%。公司拟向全体股东每股派发现金红利0.9元(含税)，合计拟派发现金红利5.1 亿元(含税)，占本年度归属于上市公司股东净利润的比例70.64%。 ...

羚锐制药（600285）公告，2025年第一季度营收为10.21亿元，同比增长12.29%；净利润为2.17亿元， 同比增长13.89%。 ...

河南羚锐制药股份有限公司 关于大股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 河南羚锐集团有限公司（以下简称"羚锐集团"）持有河南羚锐制药股份 有限公司（以下简称"公司"）股票 121,817,898 股，占公司总股本的比例为 21.48%。本次解除质押后，羚锐集团持有本公司股份累计质押数量为 26,930,000 股，占其持股数量的比例为 22.11%，占公司总股本的比例为 4.75%。 截至本公告披露日，羚锐集团及其一致行动人持有本公司股份累计质押 数量为 26,930,000 股，占其合计持股数量的比例为 21.07%，占公司总股本的比 例为 4.75%。 证券代码：600285 证券简称：羚锐制药 公告编号：2025-015 号 1 公司将根据相关法律法规要求及时履行信息披露义务。 二、大股东及其一致行动人股份质押情况 截至本公告披露日，羚锐集团及其一致行动人股份累计质押情况如下： | 股东名称 | 河南羚锐集团有限公司 | | --- | --- | | 本次解除质押股份 ...

涉及总金额4 0 8 . 5 3亿元人民币。 作者 | 私募通 来源 | 决策投资圈 （ID：PEDATAMAX） 清科创业（0 1 9 4 5 .HK）旗下私募通统计：截至本周五下午，募资、投资、上市和并购共 1 4 8起事件，涉及总金额4 0 8.53亿人民币。从交易金额来看，本周金额较大事件是： 2 0 25年3月4日，全国社会保障基金理事会投资国投电力控股股份有限公司7 0 . 0 0亿人民 币。从交易事件地域分布看，目前主要分布在上海市、北京市和江苏省，占比为上海市 2 0 .5%，北京市1 6 . 7%，江苏省14.1%。 01 本周募资情况 本周新登记股权投资基金管理人共计0家，取消备案登记4家，全年截至目前累计股权投 资基金管理人数量为11家。本周新增备案基金数量为70只，规模总计1 4 6 . 5 1亿元，本周 备案基金募资最多的为合肥市包河区产发创业投资合伙企业（有限合伙）和绵阳涪江新 兴股权投资合伙企业（有限合伙），募集20.00亿人民币。全年截至目前累计股权投资备 案基金数量为7 0 1只，规模总计5705.25亿元。（2025年2月2 8日- 2 0 2 5年3月6日） 投资金额TO ...